Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib
Jan C. Brase(Novartis (Switzerland)), Alexander Roesch(Essen University Hospital), Renáta Váraljai(Vrije Universiteit Brussel), Alexander Savchenko(Precision for Medicine (United States)), Keith T. Flaherty(Cancer Research Center), Jacob Schachter, Dirk Schadendorf(National Center for Tumor Diseases), Kurt Werner Schmid(Essen University Hospital), Elisabeth Livingstone(German Cancer Research Center), Antje Sucker(German Cancer Research Center), Deborah Castelletti(Novartis (Switzerland)), Robert Walter(Ruhrlandklinik), Naveen Dakappagari(Navidea Biopharmaceuticals (United States)), Eduard Gasal, Lisa Zimmer(The University of Sydney), Georgina V. Long(The University of Sydney), Ju Kim(Houston Methodist), Antoni Ribas(University of California, Los Angeles), Paul Nathan(Mount Vernon Hospital), Bogusława Karaszewska(State University of Applied Sciences in Konin), Tobias Schimming(Essen University Hospital), Caroline Robert(Institut Gustave Roussy), Daniel Gusenleitner, K.R. Schultz(Precision for Medicine (United States)), James E. Garrett
Cited by 20
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k